Destiny Pharma (DEST) Releases Quarterly Earnings Results, Beats Estimates By $4.30 EPS
Destiny Pharma (LON:DEST) posted its quarterly earnings data on Tuesday. The company reported GBX (11.90) (($0.16)) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of GBX (16.20) (($0.21)) by GBX 4.30 ($0.06), Digital Look Earnings reports.
LON DEST remained flat at $GBX 84 ($1.10) on Thursday. 3,935 shares of the company’s stock were exchanged, compared to its average volume of 4,205. Destiny Pharma has a twelve month low of GBX 61 ($0.80) and a twelve month high of GBX 131.40 ($1.72). The company has a market capitalization of $36.48 million and a PE ratio of -7.92.
Separately, FinnCap reiterated a “corporate” rating on shares of Destiny Pharma in a research report on Tuesday.
Destiny Pharma Company Profile
Destiny Pharma plc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of novel medicines for the treatment of infectious diseases in the United Kingdom. It is involved in developing XF-73 Nasal for the treatment of post-surgical staphylococcal infections; XF-73 Throat for the treatment of staphylococcal hospital/ventilator pneumonia infections; XF-70 Dermal for the treatment of skin burn wound infections of antibiotic resistant bacteria; and XF-70 Lung for the treatment of bacterial biofilm-associated infections.
Further Reading: What does relative strength index mean?
Receive News & Ratings for Destiny Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Destiny Pharma and related companies with MarketBeat.com's FREE daily email newsletter.